Andrew Huberman· PhD
and so it's no surprise that the early studies of checkpoint Inhibitors were also done in metastatic melanoma where you basically have more shots on goal again if I'm going to take the breaks off my immune system I might as well do it in an environment where there are more chances for my tea cells to find something to go nuts against